



The UK's Brains Bioceutical names John Boshart as new VP to its Animal Health Division

09 May 2024 | News

The core of Brains Bio's enhanced Veterinary Health Division lies in its focused approach to pharmaceutical development



The core of Brains Bio's enhanced Veterinary Health Division lies in its focused approach to pharmaceutical development

Brains Bioceutical Corp ("Brains Bio"), is strengthening its Veterinary Health Division with new leadership. John Boshart's appointment as Vice President of Veterinary API and Business Development, reflects Brains Bio's commitment to leveraging extensive pharmaceutical expertise and cutting-edge research to advance animal health care.

Brains Bio's Animal Health Division is empowered by the unique properties of its THC-free CBD API, which boasts an ultra-low detection limit of 0.000006%. This EU-GMP Certified API is pivotal in clinical and preclinical studies, including a Phase III Clinical Trial, highlighting its potential for therapeutic applications in veterinary medicine.

The CBD API is supported by rigorous regulatory credentials, including ICH-Q7 compliance, an actively maintained EU Active Substance Master File (ASMF), and a US Drug Master File (DMF) filed with the FDA. These certifications ensure the highest standards of quality and regulatory compliance essential for veterinary use.

The core of Brains Bio's enhanced Veterinary Health Division lies in its focused approach to pharmaceutical development, specifically tailored to meet the nuanced needs of the animal health sector. Recognizing the unique challenges and opportunities in veterinary medicine, the division is dedicated to pioneering the development of cannabinoid-based pharmaceuticals that offer targeted, safe, and effective treatments for animals.

This strategic focus is driven by a deep understanding of the physiological and medical requirements specific to different animal species. Through rigorous research and development, combined with stringent safety and efficacy testing, Brains Bio aims to deliver a portfolio of advanced therapeutic solutions that will not only improve health outcomes but also enhance the quality of life for animals globally.

The division will utilize Brains Bio's exclusive cannabinoid science combined with one of the limited global licenses to manufacture cannabinoid products specifically for veterinary use. This powerful combination of scientific acumen and legal empowerment sets a robust foundation for innovation in animal wellness and care.

According to a report by Grand View Research, the global animal prescription market is projected to reach approximately \$58 billion by 2026. This projection underscores the vast potential and critical need for innovative health solutions within this space. Full details on the market projections can be found at: [Grand View Research Report on Global Veterinary Care Market](#).